Valuation: Imugene Limited

Market Cap 34.51M 24.37M 21.12M 19.8M 18.05M 33.97M 2.33B 233M 91.02M 1.16B 91.48M 89.5M 3.88B P/E 2026 *
-0.71x
P/E 2027 * -1.05x
Enterprise Value 34.21M 24.16M 20.94M 19.63M 17.9M 33.67M 2.31B 231M 90.23M 1.15B 90.69M 88.72M 3.85B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.9%
Yield 2026 *
-
Yield 2027 * -
1 day-1.20%
1 week-3.53%
Current month-3.53%
1 month-15.46%
3 months-11.83%
6 months-67.84%
Current year-77.53%
1 week 0.08
Extreme 0.081
0.08
1 month 0.08
Extreme 0.081
0.1
Current year 0.08
Extreme 0.081
0.41
1 year 0.08
Extreme 0.081
0.46
3 years 0.08
Extreme 0.081
5.1
5 years 0.08
Extreme 0.081
21.25
10 years 0.08
Extreme 0.081
21.25
Manager TitleAgeSince
Director of Finance/CFO - 2025-03-03
Chief Tech/Sci/R&D Officer - 2023-08-31
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Chairman 70 2012-10-30
Director/Board Member 66 2019-04-22
Director/Board Member 61 2022-09-06
Date Insider Type Main position Quantity % Market Cap.
12/19/25 Fiscal year

Director

14,706 0.0047%
12/19/25 Fiscal year

Director

14,706 0.0047%
12/19/25 Free

Founder

124,054 0.0393%
Change 5-day change 1-year change 3-year change Capi.($)
-1.20%-3.53%-72.20%-97.38% 24.13M
+1.17%+1.09%+4.03%+15.74% 48.72B
-1.59%+2.12%+460.02%+573.56% 43.99B
-0.85%+7.95%+15.77%+80.09% 40.82B
-0.08%+3.91%+26.96%+9.86% 39.79B
0.00%+3.59%+20.51%+48.00% 32.7B
-3.61%-1.45% - - 16.84B
-2.52%-0.52%+24.35%+118.05% 16.66B
+0.72%+0.31%+4.94%+21.70% 13.95B
-1.09%+5.94%+81.46%+31.15% 13.58B
Average -0.90%+1.43%+62.87%+88.97% 26.71B
Weighted average by Cap. -0.59%+2.44%+97.52%+135.57%

Financials

2026 *2027 *
Net sales - -
Net income -56.51M -39.9M -34.58M -32.42M -29.56M -55.62M -3.81B -382M -149M -1.91B -150M -147M -6.36B -42.79M -30.21M -26.18M -24.55M -22.38M -42.11M -2.88B -289M -113M -1.44B -113M -111M -4.81B
Net Debt -300K -212K -184K -172K -157K -295K -20.21M -2.03M -791K -10.12M -795K -778K -33.76M -1M -706K -612K -574K -523K -984K -67.38M -6.75M -2.64M -33.73M -2.65M -2.59M -113M
Logo Imugene Limited
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
Employees
15
Date Price Change Volume
26-08-13 A$0.0820 -1.20% 274,340
26-08-13 A$0.0830 +1.22% 1,076,783
26-08-12 A$0.0820 0.00% 957,245
26-08-11 A$0.0820 -1.20% 2,403,301
26-08-10 A$0.0830 -2.35% 2,932,223
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0830AUD
Average target price
0.3067AUD
Spread / Average Target
+269.48%

Quarterly revenue - Rate of surprise